We use cookies on our website. Carry on browsing if you’re happy with this or find out more
Pipeline
:Driving new boundaries in drug development
Identifying and investigating new treatments to improve patient outcomes
Rich product development in four key therapeutic areas
Our pipeline
We are building a rich pipeline of assets in four main therapeutic spaces: immune diseases, immuno-oncology, haematology and infectious diseases. Our most advanced assets entered development in 2015 with first proof of concepts scheduled for readout by 2019.
Download Pipeline PDF